VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 374 filers reported holding VANECK VECTORS ETF TR in Q2 2017. The put-call ratio across all filers is 1.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,919,471 | +157.8% | 213,894 | +118.2% | 1.43% | +836.6% |
| Q2 2022 | $2,684,000 | -52.9% | 98,019 | -34.1% | 0.15% | -46.9% |
| Q1 2022 | $5,701,000 | +2109.7% | 148,649 | +2011.2% | 0.29% | +343.1% |
| Q2 2020 | $258,000 | -73.0% | 7,041 | -78.5% | 0.06% | -55.8% |
| Q4 2019 | $957,000 | -91.6% | 32,681 | -92.4% | 0.15% | -90.8% |
| Q3 2019 | $11,457,000 | +97.2% | 428,945 | +88.7% | 1.60% | +135.9% |
| Q2 2019 | $5,811,000 | +1413.3% | 227,339 | +1226.4% | 0.68% | +2012.5% |
| Q1 2019 | $384,000 | -65.9% | 17,139 | -66.5% | 0.03% | -61.0% |
| Q1 2018 | $1,126,000 | +30.6% | 51,225 | +38.1% | 0.08% | +10.8% |
| Q4 2017 | $862,000 | -59.5% | 37,095 | -60.0% | 0.07% | -59.6% |
| Q3 2017 | $2,131,000 | +886.6% | 92,806 | +850.6% | 0.18% | +1043.8% |
| Q2 2017 | $216,000 | -96.7% | 9,763 | -96.6% | 0.02% | -97.0% |
| Q1 2017 | $6,633,000 | +243.1% | 290,790 | +214.7% | 0.54% | +174.1% |
| Q4 2016 | $1,933,000 | -77.7% | 92,392 | -71.8% | 0.20% | -86.1% |
| Q3 2016 | $8,667,000 | -53.1% | 327,941 | -50.8% | 1.41% | -56.0% |
| Q2 2016 | $18,481,000 | – | 666,945 | – | 3.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |